Browse Studies — Arctuva

Phase 1

A Phase I Study of Osimertinib, Cetuximab, and Tucatinib in Advanced EGFR-Mutant NSCLC With Acquired Resistance to Osimertinib

This phase I trial tests the safety, side effects, and best dose of osimertinib, cetuximab, and tucatinib in treating patients with EFGR-mutant non-small cell …

Metastatic Lung Non-Small Cell CarcinomaRecurrent Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8

Estimated

~$10 – $7,500

Jonathan RiessNCT06067776

Insomnia in Patients With Metastatic Non Small Cell Lung Cancer

This study evaluates how common insomnia (difficulties with sleep) is in patients with lung cancer that has spread from where it first started (primary site) t…

Metastatic Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8

Estimated

~$10 – $750

Mayo ClinicNCT06472804

Phase 2

A Randomized Phase II/III Study of Docetaxel and Ramucirumab With or Without Cemiplimab for Participants Previously Treated With Platinum-Based Chemotherapy and Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)

This phase II/III Expanded Lung-MAP treatment trial compares the effect of adding cemiplimab to docetaxel and ramucirumab versus docetaxel and ramucirumab alon…

Recurrent Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8

Estimated

~$10 – $7,500

SWOG Cancer Research NetworkNCT06616584